U.S. pharma giant copyright scrapped two experimental weight loss drugs last yr—a after-every day pill, lotiglipron, as a consequence of elevated liver enzymes along with a twice-every day capsule, danuglipron, due to robust Unwanted side effects—but CEO Albert Bourla has explained the company is set to “play and get” in the obesity Place A… Read More